Ester-C gets tolerability boost

By staff reporter

- Last updated on GMT

Related tags: Ascorbic acid, Ester-c

A double-blind clinical trial of Zila's Ester-C has added more
support to the tolerability of the supplement; more support to the
company's tolerance claims.

Ester-C is an advanced form of vitamin C. Amongst the benefits is a neutral pH, which, says Zila, means that the vitamin is gentler on the stomach than traditional forms of the vitamin.

"We have known for years that Ester-C should be better tolerated than regular vitamin C, also known as ascorbic acid. This being confirmed in a double-blind, placebo-controlled human clinical study gives vitamin consumers, a proven reason in addition to the other benefits to take Ester-C,"​ said Douglas Burkett, chairman, CEO and president of Zila.

The study, published in the journal Advances in Natural Therapy​ (Vol 23, pp. 171-178), reports that 50 volunteers with sensitivity to acidic foods had less epigastric adverse effects than standard vitamin C.

The trial was designed to have an initial three-day supplementation period when the participants would receive either 1000 mg of Ester-C or 1000 mg of ascorbic acid. This was followed by a three-day washout period, and a further three days of the other form of vitamin C than from the initial supplementation period.

The occurrence and severity of gastric side-effects were self-recorded by the participants in diaries.

The researchers, from Germany-based company Analyze & realize ag, found that 56 percent of participants reported 88 mild to moderate epigastric adverse effects. Thirty-three occurred during Ester-C supplementation, and 55 from normal ascorbic acid supplementation.

These results, say the scientists, are significant.

Zila recently announced it has developed and patented a new form of Ester-C said to offer improved antioxidant and anti-carcinogenic potential. Zila said it is nearing the point where the new version will be ready for commercial distribution - although a firm release date has yet to be given.

Related news

Show more

Related products

show more

Bacillus Coagulans SNZ 1969; Efficacy & Stability

Bacillus Coagulans SNZ 1969; Efficacy & Stability

Sanzyme Biologics | 17-Feb-2020 | Technical / White Paper

SNZ 1969 has been shown to help reduce occasional gut discomfort, promote regularity, reduce occasional diarrhea, reduce occasional heartburn, and promote...

Shaping up in today’s sports nutrition market

Shaping up in today’s sports nutrition market

Lonza - Capsugel | 04-Feb-2020 | Technical / White Paper

What’s driving innovation in the sports nutrition market today? This new white paper from Lonza takes an in-depth look at the most crucial factors, from...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars